Patent ID: 11957751
Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  B  G | IPC A  B  C  G

Claim 10:
11. A method of inhibiting or reducing recurrence or metastasis of cancer in a mammal wherein TGF-β1 is expressed in the cancer or in a tumor of the cancer which comprises administering to said mammal an effective amount of an antibody molecule or fragment thereof which recognizes human and mouse transforming growth factor beta 1 (TGF-β1) and does not react with TGF-β2 and does not react with TGF-β3, wherein the antibody or fragment neutralizes activity of TGF-β1, and is an antibody or fragment comprising a heavy chain variable region comprising CDR domain sequences CDR1 GYTFTNYW (SEQ ID NO: 11), CDR2 IYPGNSDT (SEQ ID NO: 12) and CDR3 EDSRSLYYNGWDYFDY (SEQ ID NO: 5) or comprising CDR domain sequences CDR1 GYTFTNYWMH (SEQ ID NO: 3), CDR2 TIYPGNSDTN (SEQ ID NO: 4) and CDR3 EDSRSLYYNGWDYFDY (SEQ ID NO: 5), and a light chain variable region comprising CDR domain sequences CDR1 ESVDNYGISF (SEQ ID NO: 6), CDR2 YAAS (SEQ ID NO: 7) and CDR3 QQSKEVPRT (SEQ ID NO: 8).